Tofogliflozin (BioDeep_00000772273)
代谢物信息卡片
Tofogliflozin
化学式: C22H26O6 (386.17292960000003)
中文名称: 托格列净
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCC1=CC=C(C=C1)CC2=CC3=C(COC34C(C(C(C(O4)CO)O)O)O)C=C2
InChI: InChI=1S/C22H26O6/c1-2-13-3-5-14(6-4-13)9-15-7-8-16-12-27-22(17(16)10-15)21(26)20(25)19(24)18(11-23)28-22/h3-8,10,18-21,23-26H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22+/m1/s1
描述信息
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent
D007004 - Hypoglycemic Agents > D000077203 - Sodium-Glucose Transporter 2 Inhibitors
C471 - Enzyme Inhibitor > C98083 - SGLT2 Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:136041
- PubChem: 46908929
- DrugBank: DB11824
- ChEMBL: CHEMBL2110731
- CAS: 903565-83-3
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Akira Kurozumi, Masahiro Hatazaki, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Ken Kato, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura. Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial.
Cardiovascular diabetology.
2023 06; 22(1):143. doi:
10.1186/s12933-023-01879-4. [PMID: 37349722] - Homare Shimohata, Yoshiki Iwaki, Marina Yamashita, Kentaro Ohgi, Hiroshi Maruyama, Mamiko Takayasu, Kouichi Hirayama, Masaki Kobayashi. The effect of sodium-glucose cotransporter 2 inhibitor (tofogliflozin) on renal tubular damage in diabetic patients without albuminuria.
International urology and nephrology.
2022 Aug; 54(8):1907-1914. doi:
10.1007/s11255-021-03064-6. [PMID: 34843041] - Atsushi Kimura, Kenya Kamimura, Marina Ohkoshi-Yamada, Yoko Shinagawa-Kobayashi, Ryo Goto, Takashi Owaki, Chiyumi Oda, Osamu Shibata, Shinichi Morita, Norihiro Sakai, Hiroyuki Abe, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Shuji Terai. Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model.
Biochemical and biophysical research communications.
2022 03; 596(?):76-82. doi:
10.1016/j.bbrc.2022.01.086. [PMID: 35121372] - Kentaro Murakami, Yusuke Sasaki, Masato Asahiyama, Wataru Yano, Toshiaki Takizawa, Wakana Kamiya, Yoshihiro Matsumura, Motonobu Anai, Tsuyoshi Osawa, Jean-Charles Fruchart, Jamila Fruchart-Najib, Hiroyuki Aburatani, Juro Sakai, Tatsuhiko Kodama, Toshiya Tanaka. Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis.
Cells.
2022 02; 11(4):. doi:
10.3390/cells11040720. [PMID: 35203369] - Toshihiro Higashikawa, Tomohiko Ito, Takurou Mizuno, Keiichirou Ishigami, Kengo Kuroki, Naoto Maekawa, Daisuke Usuda, Takuro Morita, Kazu Hamada, Susumu Takagi, Kento Takeshima, Shinya Yamada, Ryusho Sangen, Toshihide Izumida, Hideyuki Mori, Jun Kiyosawa, Atsushi Saito, Masaharu Iguchi, Takeshi Nakahashi, Yuji Kasamaki, Akihiro Fukuda, Tsugiyasu Kanda, Masashi Okuro. Effects of tofogliflozin on adrenocorticotropic hormone, renin and aldosterone, and cortisol levels in elderly patients with diabetes mellitus: A retrospective study of a patient cohort.
Medicine.
2021 Nov; 100(45):e27638. doi:
10.1097/md.0000000000027638. [PMID: 34766565] - Satomi Kagota, Kana Maruyama-Fumoto, John J McGuire, Kazumasa Shinozuka. A Sodium Glucose Cotransporter 2 Inhibitor Fails to Improve Perivascular Adipose Tissue-Mediated Modulation of Vasodilation and Cardiac Function in Rats With Metabolic Syndrome.
Journal of cardiovascular pharmacology and therapeutics.
2021 09; 26(5):480-489. doi:
10.1177/10742484211001853. [PMID: 33764804] - Yasuhiro Matsubayashi, Akihiro Yoshida, Hideki Suganami, Momoko Oe, Takaaki Sato, Yuta Yaguchi, Kazuya Fujihara, Takaho Yamada, Shiro Tanaka, Kohei Kaku, Hirohito Sone. Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin.
Diabetes, obesity & metabolism.
2021 07; 23(7):1660-1665. doi:
10.1111/dom.14387. [PMID: 33769665] - Nozomu Yamasaki, Yoshifumi Tamura, Hideyoshi Kaga, Motonori Sato, Mai Kiya, Satoshi Kadowaki, Ruriko Suzuki, Yasuhiko Furukawa, Daisuke Sugimoto, Takashi Funayama, Yuki Someya, Saori Kakehi, Shuko Nojiri, Hiroaki Satoh, Ryuzo Kawamori, Hirotaka Watada. A decrease in plasma glucose levels is required for increased endogenous glucose production with a single administration of a sodium-glucose co-transporter-2 inhibitor tofogliflozin.
Diabetes, obesity & metabolism.
2021 05; 23(5):1092-1100. doi:
10.1111/dom.14312. [PMID: 33377253] - Kazunori Utsunomiya, Ryusuke Koshida, Seigo Kakiuchi, Masayuki Senda, Shoko Fujii, Yuji Kurihara, Ryoji Gunji, Kohei Kaku. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT).
Journal of diabetes investigation.
2021 Feb; 12(2):184-199. doi:
10.1111/jdi.13333. [PMID: 32597517] - Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Keiichi Torimoto, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Hideki Taki, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura. Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial.
Cardiovascular diabetology.
2021 01; 20(1):4. doi:
10.1186/s12933-020-01206-1. [PMID: 33397376] - Zi Li, Maki Murakoshi, Saki Ichikawa, Takeo Koshida, Eri Adachi, Chigure Suzuki, Seiji Ueda, Tomohito Gohda, Yusuke Suzuki. The sodium-glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice.
FEBS open bio.
2020 12; 10(12):2761-2770. doi:
10.1002/2211-5463.13014. [PMID: 33098615] - Haruki Yamada, Hiromasa Ohira, Fumiaki Ikegami, Koichi Nakamura, Atsushi Takahashi, Kazumichi Abe, Akihiro Inano, Sumire Shimada, Kumiko Miyata, Tomohisa Saito, Yasuhiro Ohba, Kimio Terao, Akihiro Ohnishi. Effects of Child-Pugh B Cirrhosis on Pharmacokinetics of Tofogliflozin, a New Sodium-Glucose Co-Transporter (SGLT2) Inhibitor.
Drug research.
2020 Sep; 70(9):401-409. doi:
10.1055/a-1202-0818. [PMID: 32707593] - Yasuhiro Matsubayashi, Akihiro Yoshida, Hideki Suganami, Taeko Osawa, Kazuo Furukawa, Hiroshi Suzuki, Kazuya Fujihara, Shiro Tanaka, Kohei Kaku, Hirohito Sone. Association of increased hepatic insulin clearance and change in serum triglycerides or β-hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin.
Diabetes, obesity & metabolism.
2020 06; 22(6):947-956. doi:
10.1111/dom.13980. [PMID: 31984623] - Yuichi Sato, Kiyohide Nunoi, Kohei Kaku, Akihiro Yoshida, Hideki Suganami. Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss.
Diabetes, obesity & metabolism.
2020 02; 22(2):222-230. doi:
10.1111/dom.13890. [PMID: 31608549] - Kashif Haider, Ankita Pathak, Ankit Rohilla, Md Rafi Haider, Kamal Ahmad, M Shahar Yar. Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
European journal of medicinal chemistry.
2019 Dec; 184(?):111773. doi:
10.1016/j.ejmech.2019.111773. [PMID: 31630053] - Junichi Kato, Yohei Shirakami, Masaya Ohnishi, Taku Mizutani, Masaya Kubota, Hiroyasu Sakai, Takashi Ibuka, Takuji Tanaka, Masahito Shimizu. Suppressive effects of the sodium‑glucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice.
Oncology reports.
2019 Dec; 42(6):2797-2805. doi:
10.3892/or.2019.7357. [PMID: 31638239] - Takuro Nagoya, Kenya Kamimura, Ryo Goto, Yoko Shinagawa-Kobayashi, Yusuke Niwa, Atsushi Kimura, Norihiro Sakai, Masayoshi Ko, Hiroshi Nishina, Shuji Terai. Inhibition of sodium-glucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitis-related kidney disease.
FEBS open bio.
2019 12; 9(12):2016-2024. doi:
10.1002/2211-5463.12734. [PMID: 31561285] - Yasuo Terauchi, Hisataka Fujiwara, Yuji Kurihara, Hideki Suganami, Masahiro Tamura, Masayuki Senda, Ryoji Gunji, Kohei Kaku. Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study.
Journal of diabetes investigation.
2019 Nov; 10(6):1518-1526. doi:
10.1111/jdi.13066. [PMID: 31033218] - Akira Yoshii, Tomohisa Nagoshi, Yusuke Kashiwagi, Haruka Kimura, Yoshiro Tanaka, Yuhei Oi, Keiichi Ito, Takuya Yoshino, Toshikazu D Tanaka, Michihiro Yoshimura. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
Cardiovascular diabetology.
2019 07; 18(1):85. doi:
10.1186/s12933-019-0889-y. [PMID: 31262297] - Akira Kurozumi, Yosuke Okada, Mototsugu Shimokawa, Yukiko Goshima, Takashi Otsuka, Manabu Narisawa, Keiichi Torimoto, Yoshiya Tanaka. Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor.
Diabetes technology & therapeutics.
2019 07; 21(7):385-392. doi:
10.1089/dia.2019.0099. [PMID: 31210529] - Sachiya Ikeda, Yasuki Takano, Dietmar Schwab, Agnes Portron, Nahoko Kasahara-Ito, Tomohisa Saito, Satofumi Iida. Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus.
Drug research.
2019 Jun; 69(6):314-322. doi:
10.1055/a-0662-0209. [PMID: 30103216] - Tomonari Kimura, Kazufumi Nakamura, Toru Miyoshi, Masashi Yoshida, Kaoru Akazawa, Yukihiro Saito, Satoshi Akagi, Yuko Ohno, Megumi Kondo, Daiji Miura, Jun Wada, Hiroshi Ito. Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet.
International heart journal.
2019 May; 60(3):728-735. doi:
10.1536/ihj.18-392. [PMID: 31105148] - Genya Aharon-Hananel, Itamar Raz. An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes.
Expert opinion on pharmacotherapy.
2019 May; 20(7):781-790. doi:
10.1080/14656566.2019.1583210. [PMID: 30835599] - Munehisa Bekki, Nobuhiro Tahara, Atsuko Tahara, Sachiyo Igata, Akihiro Honda, Yoichi Sugiyama, Tomohisa Nakamura, Jiahui Sun, Yuki Kumashiro, Takanori Matsui, Yoshihiro Fukumoto, Sho-Ichi Yamagishi. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
Current vascular pharmacology.
2019; 17(4):411-420. doi:
10.2174/1570161116666180515154555. [PMID: 29766812] - Toshihiro Higashikawa, Tomohiko Ito, Takurou Mizuno, Keiichirou Ishigami, Masaru Kohori, Kunihiro Mae, Ryusho Sangen, Daisuke Usuda, Atsushi Saito, Masaharu Iguchi, Yuji Kasamaki, Akihiro Fukuda, Hitoshi Saito, Tsugiyasu Kanda, Masashi Okuro. The effects of 12-month administration of tofogliflozin on electrolytes and dehydration in mainly elderly Japanese patients with type 2 diabetes mellitus.
The Journal of international medical research.
2018 Dec; 46(12):5117-5126. doi:
10.1177/0300060518790870. [PMID: 30354916] - Kazuyuki Tobe, Hideki Suganami, Kohei Kaku. Sodium-glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline.
Journal of diabetes investigation.
2018 Jul; 9(4):862-869. doi:
10.1111/jdi.12761. [PMID: 29032638] - Ren Matsuba, Ikuro Matsuba, Mototsugu Shimokawa, Yoshio Nagai, Yasushi Tanaka. Tofogliflozin decreases body fat mass and improves peripheral insulin resistance.
Diabetes, obesity & metabolism.
2018 05; 20(5):1311-1315. doi:
10.1111/dom.13211. [PMID: 29316197] - Motoshi Ouchi, Kenzo Oba, Kohei Kaku, Hideki Suganami, Akihiro Yoshida, Yasunori Fukunaka, Promsuk Jutabha, Asuka Morita, Naoyuki Otani, Keitaro Hayashi, Tomoe Fujita, Tatsuya Suzuki, Masahiro Yasutake, Naohiko Anzai. Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin.
Diabetes, obesity & metabolism.
2018 04; 20(4):1061-1065. doi:
10.1111/dom.13170. [PMID: 29171930] - Shiori Ito, Toshio Hosaka, Wataru Yano, Takahiro Itou, Misako Yasumura, Yukari Shimizu, Hideyuki Kobayashi, Takashi Nakagawa, Keisuke Inoue, Sohei Tanabe, Takuma Kondo, Hitoshi Ishida. Metabolic effects of Tofogliflozin are efficiently enhanced with appropriate dietary carbohydrate ratio and are distinct from carbohydrate restriction.
Physiological reports.
2018 03; 6(5):. doi:
10.14814/phy2.13642. [PMID: 29520981] - Soichi Takeishi, Hiroki Tsuboi, Shodo Takekoshi. Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study.
Endocrine journal.
2017 Oct; 64(10):995-1005. doi:
10.1507/endocrj.ej17-0206. [PMID: 28824042] - Yasuo Terauchi, Masahiro Tamura, Masayuki Senda, Ryoji Gunji, Kohei Kaku. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.
Diabetes, obesity & metabolism.
2017 10; 19(10):1397-1407. doi:
10.1111/dom.12957. [PMID: 28371205] - Nahoko Kasahara-Ito, Hiroyuki Fukase, Yoichiro Ogama, Tomohisa Saito, Yasuhiro Ohba, Sumire Shimada, Yasuki Takano, Tomoko Ichihara, Kimio Terao, Noboru Nakamichi, Yuji Kumagai, Sachiya Ikeda. Pharmacokinetics and Pharmacodynamics of Tofogliflozin (a Selective SGLT2 Inhibitor) in Healthy Male Subjects.
Drug research.
2017 Jun; 67(6):349-357. doi:
10.1055/s-0043-104779. [PMID: 28427104] - Shin Kawasoe, Yukiko Maruguchi, Shoko Kajiya, Hitoshi Uenomachi, Masaaki Miyata, Mariko Kawasoe, Takuro Kubozono, Mitsuru Ohishi. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
BMC pharmacology & toxicology.
2017 04; 18(1):23. doi:
10.1186/s40360-017-0125-x. [PMID: 28391776] - Jean-Luc Faillie. Pharmacological aspects of the safety of gliflozins.
Pharmacological research.
2017 04; 118(?):71-81. doi:
10.1016/j.phrs.2016.07.001. [PMID: 27389050] - Takahiro Tosaki, Hideki Kamiya, Tatsuhito Himeno, Yoshiro Kato, Masaki Kondo, Kaori Toyota, Tomoyo Nishida, Megumi Shiroma, Kaori Tsubonaka, Hitomi Asai, Miho Moribe, Yuki Nakaya, Jiro Nakamura. Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes.
Internal medicine (Tokyo, Japan).
2017; 56(6):597-604. doi:
10.2169/internalmedicine.56.7196. [PMID: 28321056] - Yuji Ishibashi, Takanori Matsui, Sho-Ichi Yamagishi. Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals.
Diabetes & vascular disease research.
2016 11; 13(6):438-441. doi:
10.1177/1479164116657304. [PMID: 27407083] - Shinji Kobuchi, Megumi Matsuno, Etsuko Fukuda, Yukako Ito, Toshiyuki Sakaeda. Development and validation of an LC-MS/MS method for the determination of tofogliflozin in plasma and its application to a pharmacokinetic study in rats.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2016 Aug; 1027(?):227-33. doi:
10.1016/j.jchromb.2016.05.053. [PMID: 27304784] - Atsushi Obata, Naoto Kubota, Tetsuya Kubota, Masahiko Iwamoto, Hiroyuki Sato, Yoshitaka Sakurai, Iseki Takamoto, Hisayuki Katsuyama, Yoshiyuki Suzuki, Masanori Fukazawa, Sachiya Ikeda, Kaito Iwayama, Kumpei Tokuyama, Kohjiro Ueki, Takashi Kadowaki. Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice.
Endocrinology.
2016 Mar; 157(3):1029-42. doi:
10.1210/en.2015-1588. [PMID: 26713783] - Y Ishibashi, T Matsui, S Yamagishi. Tofogliflozin, A Highly Selective Inhibitor of SGLT2 Blocks Proinflammatory and Proapoptotic Effects of Glucose Overload on Proximal Tubular Cells Partly by Suppressing Oxidative Stress Generation.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
2016 Mar; 48(3):191-5. doi:
10.1055/s-0035-1555791. [PMID: 26158396] - Atsuo Tahara, Toshiyuki Takasu, Masanori Yokono, Masakazu Imamura, Eiji Kurosaki. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Journal of pharmacological sciences.
2016 Mar; 130(3):159-69. doi:
10.1016/j.jphs.2016.02.003. [PMID: 26970780] - N Kasahara, H Fukase, Y Ohba, T Saito, K Miyata, S Iida, Y Takano, S Ikeda, M Harigai, K Terao. A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Drug research.
2016 Feb; 66(2):74-81. doi:
10.1055/s-0035-1549967. [PMID: 26158794] - Masanori Fukazawa, Takumi Nagata, Masayuki Suzuki, Yoshiyuki Suzuki, Yoshiki Kawabe. Pharmacological analysis of SGLT2 inhibitor (tofogliflozin) using in vivo glucose clamp and titration protocols in rats and cynomolgus monkeys.
Nihon yakurigaku zasshi. Folia pharmacologica Japonica.
2016; 148(5):259-265. doi:
10.1254/fpj.148.259. [PMID: 27803439] - S Ikeda, Y Takano, O Cynshi, R Tanaka, A D Christ, V Boerlin, U Beyer, A Beck, C Ciorciaro, M Meyer, T Kadowaki. A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.
Diabetes, obesity & metabolism.
2015 Oct; 17(10):984-93. doi:
10.1111/dom.12538. [PMID: 26179482] - Mizuki Yamane, Kosuke Kawashima, Koji Yamaguchi, Shunsuke Nagao, Mika Sato, Masayuki Suzuki, Kiyofumi Honda, Hitoshi Hagita, Olaf Kuhlmann, Agnes Poirier, Stephen Fowler, Christoph Funk, Sandrine Simon, Yoshinori Aso, Sachiya Ikeda, Masaki Ishigai. In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP.
Xenobiotica; the fate of foreign compounds in biological systems.
2015 Mar; 45(3):230-8. doi:
10.3109/00498254.2014.976296. [PMID: 25350082] - R F Rosenwasser, J N Rosenwasser, D Sutton, R Choksi, B Epstein. Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes.
Drugs of today (Barcelona, Spain : 1998).
2014 Nov; 50(11):739-45. doi:
10.1358/dot.2014.50.11.2232267. [PMID: 25525634] - M Suzuki, M Hiramatsu, M Fukazawa, M Matsumoto, K Honda, Y Suzuki, Y Kawabe. Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans.
Diabetes, obesity & metabolism.
2014 Jul; 16(7):622-7. doi:
10.1111/dom.12259. [PMID: 24400675] - Takumi Nagata, Masayuki Suzuki, Masanori Fukazawa, Kiyofumi Honda, Mizuki Yamane, Ayae Yoshida, Hiroko Azabu, Hidekazu Kitamura, Naoto Toyota, Yoshiyuki Suzuki, Yoshiki Kawabe. Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys.
American journal of physiology. Renal physiology.
2014 Jun; 306(12):F1520-33. doi:
10.1152/ajprenal.00076.2014. [PMID: 24761001] - Manfred Zell, Christophe Husser, Olaf Kuhlmann, Dietmar Schwab, Takahide Uchimura, Tomonori Kemei, Kosuke Kawashima, Mizuki Yamane, Axel Pähler. Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans.
Xenobiotica; the fate of foreign compounds in biological systems.
2014 Apr; 44(4):369-78. doi:
10.3109/00498254.2013.839847. [PMID: 24074237] - T Nagata, T Fukuzawa, M Takeda, M Fukazawa, T Mori, T Nihei, K Honda, Y Suzuki, Y Kawabe. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.
British journal of pharmacology.
2013 Oct; 170(3):519-31. doi:
10.1111/bph.12269. [PMID: 23751087] - Dietmar Schwab, Agnes Portron, Zoe Backholer, Berthold Lausecker, Kosuke Kawashima. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.
Clinical pharmacokinetics.
2013 Jun; 52(6):463-73. doi:
10.1007/s40262-013-0051-z. [PMID: 23494983] - Takumi Nagata, Masanori Fukazawa, Kiyofumi Honda, Tatsuo Yata, Mio Kawai, Mizuki Yamane, Naoaki Murao, Koji Yamaguchi, Motohiro Kato, Tetsuya Mitsui, Yoshiyuki Suzuki, Sachiya Ikeda, Yoshiki Kawabe. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
American journal of physiology. Endocrinology and metabolism.
2013 Feb; 304(4):E414-23. doi:
10.1152/ajpendo.00545.2012. [PMID: 23249697] - Masayuki Suzuki, Kiyofumi Honda, Masanori Fukazawa, Kazuharu Ozawa, Hitoshi Hagita, Takahiro Kawai, Minako Takeda, Tatsuo Yata, Mio Kawai, Taku Fukuzawa, Takamitsu Kobayashi, Tsutomu Sato, Yoshiki Kawabe, Sachiya Ikeda. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
The Journal of pharmacology and experimental therapeutics.
2012 Jun; 341(3):692-701. doi:
10.1124/jpet.112.191593. [PMID: 22410641]